The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata
Open accessAbstract
Loss of nigrostriatal dopaminergic neurons in Parkinson's disease (PD) leads to increased activity of glutamatergic neurons in the subthalamic nucleus (STN). Recent studies reveal that the resultant increase in STN-induced excitation of basal ganglia output nuclei is responsible for the disabling motor impairment characteristic of PD. On the basis of this, it is possible that any manipulation that reduces activity at excitatory STN synapses onto basal ganglia output nuclei could be useful in the treatment of PD. We now report that group II metabotropic glutamate receptors (mGluRs) are presynaptically localized on STN terminals and that activation of these receptors inhibits excitatory transmission at STN synapses. In agreement with the hypothesis that this could provide a therapeutic benefit in PD, a selective agonist of group II mGluRs induces a dramatic reversal of catalepsy in a rat model of PD. These results raise the exciting possibility that selective agonists of group II mGluRs could provide an entirely new approach to the treatment of PD. These novel therapeutic agents would provide a noninvasive pharmacological treatment that does not involve the manipulation of dopaminergic systems, thus avoiding the problems associated with current therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“It was shown that activation of mGluR2s can also regulate release of other neurotransmitters: it can inhibit GABA release via a presynaptic mechanism (Bradley et al. 2000; Pilc et al. 2008).”
From Short- and Long-Term Consequences of Nicotine Exposure during Adolescence for Prefrontal Cortex Neuronal Network Function (2012) · cites this paper as Bradley et al. 2000
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation
Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Bas, J. L., Perret, J., Benabid, A., & Broussolle, E. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90062-4 · Cited by 1,480
Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease.
Laitinen, L., Bergenheim, A. T., & Hariz, M. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.76.1.0053 · Cited by 1,120
Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P. J., Neki, A., Abe, T., Nakanishi, S., et al. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07503.1997 · Cited by 1,116
Kita, H., & Kitai, S. T. (1987) · The Journal of Comparative Neurology · doi:10.1002/cne.902600309 · Cited by 591
Alternative excitotoxic hypotheses
Albin, R. L., & Greenamyre, J. T. (1992) · Neurology · doi:10.1212/wnl.42.4.733 · Cited by 574 · cited 1×
“Furthermore, glutamate has been implicated as an excitotoxic agent in PD (Albin and Greenamyre, 1992; Rodriguez et al., 1998), suggesting that increased excitatory drive to the SNc may contribute to the progressive loss of SNc dopaminergic neurons in PD.”
BackgroundBaron, M. S., Vitek, J. L., Green, J., Kaneoke, Y., Hashimoto, T., Turner, R. S., Woodard, J. L., DeLong, M. R., Bakay, R. A. E., Cole, S. A., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400305 · Cited by 559
Ohishi, H., Shigemoto, R., Nakanishi, S., & Mizuno, N. (1993) · The Journal of Comparative Neurology · doi:10.1002/cne.903350209 · Cited by 516
Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat
Testa, C. M., Standaert, D. G., Young, A. R., & Penney, J. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-05-03005.1994 · Cited by 512
Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection
Rodríguez‐Oroz, M., Obeso, J. A., & Olanow, C. W. (1998) · Annals of Neurology · doi:10.1002/ana.410440726 · Cited by 399
Luján, R., Roberts, J. D. B., Shigemoto, R., Ohishi, H., & Somogyi, P. (1997) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(97)00051-3 · Cited by 395
Research works printed but not linked: 1
- Wichmann T DeLong MR (1997) Physiology of the basal ganglia and pathophysiology of movement disorders of basal ganglia origin. in Movement disorders: neurological principles and practice, ed Watts RL (McGraw-Hill, New York), pp 87–97.
Cited by
Sorted by citations
Items 101–141 of 141
Ossowska, K., Konieczny, J., Pilc, A., & Wolfarth, S. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03005-6 · Cited by 13
Lee, J. J., & Croucher, M. J. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00837-0 · Cited by 12
Metabotropic Glutamate Receptors
Ossowska, K. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-852-6_5 · Cited by 11
Lorenc‐Koci, E., Wardas, J., Wolfarth, S., & Pilc, A. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02438-6 · Cited by 11
Alborghetti, M., Ceccherelli, A., Caridi, M., Nicoletti, F., Battaglia, G., & Bruno, V. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01138-1 · Cited by 11
Pharmacological approaches to disease-modifying therapies in Parkinson’s disease
O’Neill, M. J., & Siemers, E. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.6.819 · Cited by 10
Dąbrowska‐Bouta, B., Strużyńska, L., Chalimoniuk, M., Frontczak‐Baniewicz, M., & Sułkowski, G. (2015) · Folia Neuropathologica · doi:10.5114/fn.2015.56546 · Cited by 11
Lee, H. S., Chong, W., Han, S. K., Lee, M. H., & Ryu, P. D. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00490-5 · Cited by 9
Yang, H., Zhang, C., Zheng, H., Xiong, W., Zhou, Z., Xu, T., & Ding, J. P. (2005) · European Biophysics Journal · doi:10.1007/s00249-005-0486-8 · Cited by 8
de Labra, C., Rivadulla, C., & Cudeiro, J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03847.x · Cited by 7
Frouni, I., Kwan, C., Belliveau, S., Hamadjida, A., Bédard, D., Nuara, S. G., Gourdon, J. C., & Huot, P. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175429 · Cited by 6
Metabotropic glutamate receptors
Pilc, A., & Ossowska, K. (2007) · Amino Acids · doi:10.1007/s00726-006-0315-0 · Cited by 6
Presti‐Silva, S. M., Rodrigues‐Ribeiro, L., Gorshkov, V., Kjeldsen, F., Verano‐Braga, T., & Pires, R. G. W. (2025) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.70006 · Cited by 5
Glutamate and Neurodegenerative Disease
Schaeffer, E., & Duplantier, A. J. (2010) · Topics in medicinal chemistry · doi:10.1007/7355_2010_11 · Cited by 5
Marek, G. J., Kinon, B. J., McKinzie, D. L., Schkeryantz, J. M., & Monn, J. A. (2012) · doi:10.1002/9781118309421.ch6 · Cited by 5
Metabotropic Glutamate Receptor–Dopamine Interactions in the Basal Ganglia Motor Circuit
Johnson, K. A., & Conn, P. J. (2011) · Frontiers in neuroscience · doi:10.1201/b11284-2 · Cited by 4
Self-citationCurrent Radioligands for the PET Imaging of Metabotropic Glutamate Receptors
Mu, L., & Ametamey, S. M. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_15 · Cited by 4
Metabotropic Glutamate Receptors and Parkinson’s Disease: Basic and Preclinical Neuroscience
Gubellini, P., Iskhakova, L., Smith, Y., & Amalric, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-56170-7_3 · Cited by 4
Metabotropic Glutamate Receptor Ligands as Novel Therapeutic Agents
Brady, A. E., & Conn, P. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-055-3_14 · Cited by 4
Self-citationJohnson, K. A. (2021) · Neuromethods · doi:10.1007/978-1-0716-1107-4_7 · Cited by 2
Bishop, J. R., & Ellingrod, V. L. (2007) · Current Pharmacogenomics · doi:10.2174/157016007780077220 · Cited by 2
Chemical Anatomy and Synaptic Connectivity of the Globus Pallidus and Subthalamic Nucleus
Smith, Y., Charara, A., Hanson, J. E., Hubert, G. W., & Kuwajima, M. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1235-6_10 · Cited by 2
Masilamoni, G. J., & Smith, Y. (2017) · The Receptors · doi:10.1007/978-3-319-56170-7_6 · Cited by 2
Henchcliffe, C., & Beal, M. F. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83027-2 · Cited by 2
Physiological Roles of Multiple Metabotropic Glutamate Receptor Subtypes in the Rat Basal Ganglia
Conn, P. J., Awad, H., Bradley, S. R., Marino, M. J., Rouse, S. T., & Wittmann, M. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1235-6_12 · Cited by 2
Self-citationZong, B., Yu, F., Zhang, X., Pang, Y., Li, F., Sun, P., & Li, L. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06021-5 · Cited by 1
Glutamatergic Receptors in Parkinson’s Disease
Sampedro, A., Tarragón, E., Yuste, J. E., Ros‐Bernal, F., Ortiz, V., Campuzano, C. M., Gómez, A., Ros, C. M. B., Fernández‐Villalba, E., & Herrero, M. T. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_154 · Cited by 1
Volta, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815950-7.00009-6 · Cited by 1
The Roles of Metabotropic Glutamate Receptors in Modulating the Activity of the Subthalamic Nucleus
Awad, H., & Conn, P. J. (2002) · Advances in behavioral biology · doi:10.1007/978-1-4615-0715-4_13 · Cited by 1
Self-citationNon‐Dopaminergic Approaches to the Treatment of Parkinson's Disease
Fox, S. H., & Brotchie, J. M. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch38 · Cited by 1
Toward Maturation of the Vestibular System: Neural Circuits and Neuronal Properties
Lai, C., Tse, Y.-C., Shum, D. K., & Chan, Y. (2004) · Neuroembryology and Aging · doi:10.1159/000096794
Metabotrobic Glutamate Receptor mGluR4 as a Novel Target for Parkinson's Disease
Levy, A. I. (1999) · Defense Technical Information Center (DTIC)
Chong, Z. Z., Kang, J., & Maiese, K. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0282-1_10
Functional Organization of the Midbrain Substantia Nigra
Brown, J. (2011) · Frontiers in neuroscience · doi:10.1201/b11284-9
Learning to focus and focusing to learn : more than a cortical trick
Dhawan, S. S. (2018) · St Andrews Research Repository (St Andrews Research Repository)
Machine learning discriminates parkinsonian movement disorders in zebrafish
Hughes, G. L. (2019) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Modulation of basal ganglia function by metabotropic glutamate receptors
Johnson, K. A. (2013)
Current Radioligands for the PET Imaging of Metabotropic Glutamate Receptors
Mu, L., & Ametamey, S. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_13
Etude des interactions entre neurones et astrocytes au sein de la substance noire réticulée
Barat, É. (2012) · theses.fr (ABES) · doi:10.70675/f11d01d6z964dz424cza1d8zb0eff9c791ab
Metadata
- Authors
- Bradley, S. R., Marino, M. J., Wittmann, M., Rouse, S. T., Awad, H., Levey, A. I., & Conn, P. J.
- Affiliations
- University of Tübingen (DE)
- Emory University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2000-05-01
- Volume
- 20
- Issue
- 9
- Pages
- 3085-3094
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6773118
- OpenAlex
- W1926939570
- Cited by
- 141
- References
- 54
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Journal of Neuroscience Nursing
- Funders
- National Parkinson Foundation
- Emory University
- National Institutes of Health
- U.S. Army
- Parkinsonfonden
- Topics
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- group II metabotropic glutamate receptors, substantia nigra pars reticulata, subthalamic nucleus, Parkinson's disease, basal ganglia, glutamatergic synapses, presynaptic inhibition, catalepsy, mGluR agonists, glutamatergic neurons
- MeSH terms
- Animals, Bridged Bicyclo Compounds, Catalepsy, Haloperidol, Male, Parkinson Disease, Substantia Nigra, Rats, Sprague-Dawley, Receptors, Presynaptic, Receptors, Metabotropic Glutamate, Dopamine Antagonists, Excitatory Amino Acid Agonists, Glutamic Acid, Excitatory Postsynaptic Potentials, Subthalamic Nucleus, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
